Key facts
- This page summarizes Lloyd Sems's Form 4 filing for Cyclacel Pharmaceuticals, Inc. (CYCC).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 16 Jun 2022, 16:11.
Lloyd Sems - 14 Jun 2022 Form 4 Insider Report for Cyclacel Pharmaceuticals, Inc. (CYCC)
- Reporting relationship
- Director
- Issuer ticker
- CYCC
- Reported as of
- 14 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Jun 2022, 16:11:53 UTC
- Prior SEC filing
- 17 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lloyd Sems
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Lloyd Sems filed Form 4 for Cyclacel Pharmaceuticals, Inc. (CYCC) on 16 Jun 2022.
Change
- Previous filing in this sequence was filed on 17 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CYCC
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +15,822
- Change %
- +666%
- Price
- $0.000000
- Shares after
- 18,196
- Date
- 14 Jun 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CYCC
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +31,645
- Change %
- Price
- $0.000000
- Shares after
- 31,645
- Date
- 14 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 31,645
- Exercise price
- $1.11
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The reporting person received an award of 15,822 restricted stock units on June 14, 2022, which shall vest in full on June 14, 2023.
Footnote F2
These options were granted to Mr. Sems for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc.